Aquestive Therapeutics (AQST) EBITDA (2017 - 2026)

Aquestive Therapeutics has reported EBITDA for 10 years, with the latest figure at -$8.2 million in Q2 2026.

• On a quarterly basis, EBITDA rose 27.67% year-over-year to -$8.2 million in Q2 2026; TTM through Jun 2026 was -$52.7 million, a 0.27% change from a year earlier, with the FY2025 full-year figure at -$71.1 million, down 130.9% from the prior year.
• EBITDA was -$8.2 million for Q2 2026 at Aquestive Therapeutics, down from -$4.2 million in the prior quarter.
• The five-year high for EBITDA was $55000.0 in Q2 2024, with the low at -$28.8 million in Q4 2025.
• Average EBITDA over 5 years is -$9.5 million, with a median of -$8.9 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: EBITDA jumped 101.31% in 2024, then sank 20769.09% in 2025.
• Over 5 years, EBITDA stood at -$10.7 million in 2022, then jumped by 63.49% to -$3.9 million in 2023, then plunged by 247.2% to -$13.6 million in 2024, then sank by 112.38% to -$28.8 million in 2025, then soared by 71.49% to -$8.2 million in 2026.
• The last three EBITDA figures came in at -$8.2 million (Q2 2026), -$4.2 million (Q1 2026), and -$28.8 million (Q4 2025), per Business Quant data.